Trial
NCT05498220
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Genentech, Inc.
Condition
Diffuse Large B-cell Lymphoma
Intervention
Polatuzumab vedotin (PV)
Why stopped
Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-16